Division of Vascular Surgery, Cardiovascular Institute, Hospital Clínic, University of Barcelona, Barcelona, Spain.
Division of Vascular Surgery, Cardiovascular Institute, Hospital Clínic, University of Barcelona, Barcelona, Spain.
Ann Vasc Surg. 2021 Aug;75:29-44. doi: 10.1016/j.avsg.2021.03.024. Epub 2021 Apr 5.
Branched and fenestrated endografts (fEVAR/bEVAR) are complex techniques used to treat thoracic aorta pathologies involving the aortic arch. This systematic review aims to determine all the reported results regarding these techniques in the aortic arch, in order to describe their clinical outcomes.
A systematic review of the literature was performed, considering all articles published until October 2019. PubMed, Cochrane database resources were used. The protocol of the study was previously registered in the Prospero database (CRD42020147037). Primary exclusion criteria included opinion articles, merely technique descriptions, articles without the follow-up of at least 1 month, studies conducted on animals, mixed treatments, and ongoing trials without published data. Included variables were study design, aortic pathology, type of endovascular technique (fEVAR/bEVAR), endograft manufacturing, number of fenestrations/branches and type of bridge stents. Technical success, complications during surgery and follow-up were also described.
From a total of 164 articles, 29 (28 retrospective, 1 prospective) were analyzed with a total of 693 cases (341 fEVAR and 352 bEVAR). The most common indications for repair were aneurysm (54.8%) and dissection (40%). Only fEVAR and bEVAR were considered, but different endograft materials and techniques were used and, therefore, reported upon in the current review. Zenith Alpha Thoracic Endovascular Graft was the most representative (24% of cases). Custom made, off-the-shelf, physician modified and in situ fenestrated endografts were also used in 39%, 22.4%, 18.6% and 18.9% of cases, respectively. Bridge stents were implanted in the 50.5% of cases. Technical success rate was 96%. The main intraoperative complication was the endoleak (5.2%) followed by stroke (4.8%). The in-hospital mortality was 2.5%. The mean follow-up was 18.5 months. The mortality related to the main operation during follow-up was 3.2% and not directly related to the main operation was 11.3%. During the follow-up, 92 cases (13.3%) in total had to undergo through a reintervention, 46.7% with endovascular repair and 26.1% with open surgical repair (the rest were not specified).
published experience with bEVAR and fEVAR in the aortic arch showed acceptable short-term effectiveness and safety. More well-conducted prospective clinical studies with long term follow-up, combined with comparative meta-analysis, are needed to elucidate the real benefit of those endovascular techniques in the aortic arch pathology.
分支型和开窗型腔内移植物(fEVAR/bEVAR)是用于治疗涉及主动脉弓的胸主动脉病变的复杂技术。本系统评价旨在确定所有关于这些技术在主动脉弓中的报告结果,以便描述其临床结果。
对文献进行了系统回顾,考虑了截至 2019 年 10 月发表的所有文章。使用了 PubMed、Cochrane 数据库资源。该研究的方案已预先在 Prospero 数据库(CRD42020147037)中注册。主要排除标准包括意见文章、仅技术描述、随访时间少于 1 个月的文章、动物研究、混合治疗以及无已发表数据的正在进行的试验。纳入的变量包括研究设计、主动脉病变、血管内技术类型(fEVAR/bEVAR)、移植物制造、开窗/分支数量和桥接支架类型。还描述了手术期间和随访期间的技术成功率和并发症。
总共从 164 篇文章中分析了 29 篇(28 篇回顾性,1 篇前瞻性),共有 693 例(341 例 fEVAR 和 352 例 bEVAR)。修复的最常见适应症是动脉瘤(54.8%)和夹层(40%)。仅考虑了 fEVAR 和 bEVAR,但使用了不同的移植物材料和技术,并在当前综述中进行了报道。Zenith Alpha 胸主动脉腔内移植物是最具代表性的(占病例的 24%)。定制、现成、医生修改和原位开窗移植物分别在 39%、22.4%、18.6%和 18.9%的病例中使用。桥接支架植入在 50.5%的病例中。技术成功率为 96%。主要的术中并发症是内漏(5.2%),其次是中风(4.8%)。住院死亡率为 2.5%。平均随访时间为 18.5 个月。随访期间,主要手术相关死亡率为 3.2%,非直接与主要手术相关的死亡率为 11.3%。在随访期间,共有 92 例(13.3%)患者需要进行再次介入治疗,其中 46.7%为血管内修复,26.1%为开放手术修复(其余未具体说明)。
发表的关于 bEVAR 和 fEVAR 在主动脉弓中的经验显示出可接受的短期效果和安全性。需要更多经过良好设计的前瞻性临床研究,结合长期随访和比较性荟萃分析,以阐明这些血管内技术在主动脉弓病变中的真正益处。